INVESTORS
Our model was designed to reduce investment risk in life sciences projects, increase profits, and generate social impact
LAB+ offers investors the opportunity to participate in impactful ventures by collaborating with leading global researchers in life sciences. Our long-term capital investment strategy aims to generate attractive returns while advancing cutting-edge technologies and therapies that have the potential to revolutionize healthcare.
Our portfolio of start-ups provide innovative solutions to global issues in the medical and environmental sectors, enhancing everyone’s quality of life.
We believe in the exceptional talents and capabilities of scientists and entrepreneurs in Latin America.
Our investments target a diverse range of sectors within the life sciences industry, including:
• Drug Discovery & Pharmaceuticals
• Ag-Tech & Food-Tech
• Med-Tech
• Healthcare Services
• Diagnostics and Biomedicine
We have proven expertise through a team that comprises seasoned professionals with deep knowledge in the life sciences sector, ensuring informed investment decisions and strategic guidance for our portfolio companies.
We work closely with the start-ups, providing strategic support, industry connections, and operational insights to accelerate their growth.
De-risking: the strategy to minimize risks
The LAB+ de-risking model involves personalized mentorship for start-up founders, focusing on developing a robust action plan to bring their innovations to market through strategic planning.
This includes in-depth market analysis, feasibility studies, and pilot projects to test the viability of ideas before commiting significant resources.
As a venture builder, LAB+ also provides financial support and strategic planning, reinforcing start-up growth, mitigating the risk of cash flow issues and providing a safety financial background for early-stage startups.
Our success stories are the catalysts behind the creation of LAB+
The Institut Pasteur de Montevideo began applying a start-up development model in 2016 with the aim of using knowledge to benefit society. In an ecosystem where science and knowledge generation were traditionally academic, the institute ventured to implement innovative programs. After a successful learning curve, these initiatives led to the creation of several companies and success stories.
One of the most prominent is Eolo Pharma. Boosted by the General Partners of LAB+, this pharmaceutical company develops new therapies for cardiometabolic, neurodegenerative, and autoimmune disorders.
Eolo Pharma has successfully advanced an original therapeutic compound —a drug for the prevention and treatment of obesity and its associated metabolic diseases— into human clinical trial phases, marking a national milestone. The achievement has positioned the compound as an innovative global therapy.
Initially backed by CITES and with its R&D laboratories based at the Institut Pasteur de Montevideo, Eolo Pharma continued its development with support from Ficus Advisory, which led the Series A funding round in 2019 to fuel the startup’s growth.